Transgene Biotek Ltd — Important, 12-01-2026: Company Update

The company has released a statement detailing deviations in the use of funds from its Rights Issue. Of the 1.50 Cr earmarked for working capital, 1.20 Cr has been utilized, with the remaining 0.30 Cr temporarily held in a fixed deposit. This is due to a slight delay in the expansion project, for which 2.00 Cr was allocated, with 1.00 Cr spent so far. The Board reviewed and approved this temporary parking of unutilized funds. Full utilization is expected as the project progresses, ensuring transparency on capital deployment.